Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans

Growth Factors

Volumn 18, Issue 3, 2000, Pages 215-226

  De Boer, R H ^a   Roskos, L K ^a   Cheung, E ^a   Fox, S ^a   Basser, R L ^a   Marty, J ^a   Begley, C G ^a   Cebon, J ^a  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

Author keywords

PEG rHuMGDF; Pharmacokinetics; Phase I study; Serum concentration

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; MACROGOL; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; THROMBOPOIETIN;

ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MEGAKARYOPOIESIS; NONLINEAR SYSTEM; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; STEADY STATE; THROMBOCYTE COUNT; THROMBOCYTOSIS;

EID: 0034446499     PISSN: 08977194     EISSN: None     Source Type: Journal    
DOI: 10.3109/08977190009003246     Document Type: Article

References (32)

1. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoesis in mice lacking the thrombopoietin receptor c-mpl
2. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl
3. Macrophages specifically regulate the concentration of their own growth factor in the circulation
4. Randomised, blinded, placebo-controlled phase I trial of pegylatedrecombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with filgrastim after dose-intensive chemotherapy in patients with advanced cancer
5. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer
6. Pharmacokinetics of recombinant human thrombopoietin (rhTPO) after intravenous administration in cancer patients
7. Thromobopoietin (c-Mpl-ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increase megakaryocyte ploidy in vitro
8. Cloning and characterization of the human megakaryocyte growth and development factor (MGDF) gene
9. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional
10. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl-ligand
11. Regulation of thrombopoietin levels by c-Mpl-mediated binding to platelets
12. Genomic structure, chromosomal localisation, and conserved alternative splice forms of thrombopoietin
13. Regulation of platelet production and function by megakaryocyte growth and development factor in non-human primates
14. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice
15. Pharmacological effects of recombinant human granulocyte colony-stimulating factor modified by polyethylene glycol on anticancer drug-induced neutropenia in mice
16. Purification and characterisation of thrombopoietin derived from thrombocytopenic rat plasma
17. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production
18. The reciprocal relationship of thrombopoietin (c-Mpl-ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit
19. Evidence for a novel in vivo control mechanism of granulopoiesis: Mature cell-regulated control of a regulatory growth factor
20. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl-ligand thrombopoietin
21. Murine thrombopoietin mRNA levels are modulated by platelet count
22. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis
23. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2
24. Megakaryocyte growth and development factor: Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia
25. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation
26. Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF
27. Mp1-ligand (MGDF) alone and in combination with Stem Cell Factor (SCF) promotes proliferation and survival of human megakaryocyte, erythroid and granulocyte/macrophage progenitors
28. A cytokinetic model of platelet (PLT) production and destruction following administration of PEG-rHuMGDF
29. Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets
30. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice
31. Modification of recombinant granulocyte colony-stimulating factor (rhFILGRASTIM) and its derivative ND 28 with polyethylene glycol
32. In vitro megakaryocytopoietic and thrombopoietic activity of c-Mpl-ligand (TPO) on purified murine hematopoietic stem cells